Text Size

Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan

Nakazawa T., Takahashi K., Kuwayama Y., Nomura A., Shimada F.


  • 2022
  • Advances in Therapy
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Post-Approval studies/RWE

  • Affiliations

    Department of Ophthalmology, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan; Department of Ophthalmology, Kansai Medical University, 2-5-1 Shin-machi, Osaka, Hirakata, 573-1010, Japan; Fukushima Eye Clinic, 5-6-16, Fukushima, Fukushima-ku, Osaka, 553-0003, Japan; Santen Pharmaceutical Co., Ltd, 4-20, Ofukacho, Kita-ku, Osaka, 530-8552, Japan

Related Publications

Associations between Clustered Visual Field Progression and Locations of Disc Hemorrhages in Glaucoma: A Three-year Prospective Study

Akagi T.; Fukuchi T.; Higashide T.; Udagawa S.; Ohkubo S.; Sugiyama K.; Tanihara H.; Araie M.; Tomita G.; Matsumoto C.; Tomidokoro A.; Hangai M.; Kawata H.; Inai M.; Tanaka Y.; SVF Prospector Study Group


Proteome-Wide Analysis of Autoantibodies in Open-Angle Glaucoma in Japanese Population: A Pilot Study

Takada N.; Ishikawa M.; Sato K.; Kunikata H.; Ninomiya T.; Hanyuda A.; Fukuda E.; Yamaguchi K.; Ono C.; Kirihara T.; Shintani C.; Tsusu C.; Osanai A.; Goshima N.; Izumi Y.; Zorumski C.F.; Nakazawa T.


Bioequivalence of Preservative-free and Preserved Omidenepag Isopropyl (OMDI) 0.002% Ophthalmic Solutions in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Results from the Phase 3 DAISY Study

Aihara M.; Lu F.; Ikeda T.; Odani-Kawabata N.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022